Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Denali Therapeutics, with 13 buys, two holds and one sell among 16 covering firms. The average 12-month price target is approximately $35.92, above the stock’s reported $24.83 opening price.
• Denali reported a quarterly loss of $0.68 per share, missing the consensus estimate of a $0.51 loss, while revenue of $3.60 million exceeded expectations of $2.15 million.
• Institutional investors own 92.92% of the company, with Goldman Sachs increasing its stake by 58.1% in the first quarter. Denali is developing therapies for neurodegenerative diseases, including Parkinson’s and Alzheimer’s disease.

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has received a consensus rating of "Moderate Buy" from the sixteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $35.9167.

A number of equities analysts recently weighed in on the stock. Sanford C. Bernstein restated a "hold" rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. Robert W. Baird set a $34.00 price target on shares of Denali Therapeutics in a report on Friday. Stifel Nicolaus set a $41.00 price target on shares of Denali Therapeutics in a research note on Monday, June 22nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Denali Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen upgraded Denali Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday.

Denali Therapeutics Price Performance

Shares of Denali Therapeutics stock opened at $24.83 on Friday. The company has a market capitalization of $3.94 billion, a price-to-earnings ratio of -8.74 and a beta of 1.01. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. The stock's 50-day simple moving average is $23.54 and its 200-day simple moving average is $21.28. Denali Therapeutics has a 52 week low of $12.58 and a 52 week high of $27.30.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to analysts' expectations of $2.15 million. During the same period in the prior year, the company earned ($0.72) EPS. As a group, analysts expect that Denali Therapeutics will post -2.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DNLI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Denali Therapeutics by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company's stock valued at $1,210,000 after buying an additional 3,432 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Denali Therapeutics by 58.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company's stock worth $22,732,000 after buying an additional 614,555 shares during the period. Empowered Funds LLC lifted its stake in shares of Denali Therapeutics by 11.0% during the 1st quarter. Empowered Funds LLC now owns 20,639 shares of the company's stock worth $281,000 after acquiring an additional 2,052 shares during the last quarter. Woodline Partners LP boosted its holdings in Denali Therapeutics by 13.5% during the 1st quarter. Woodline Partners LP now owns 113,517 shares of the company's stock valued at $1,543,000 after acquiring an additional 13,517 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Denali Therapeutics by 1.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company's stock valued at $2,681,000 after acquiring an additional 3,210 shares during the period. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source